{'fraction_non_alphanumeric': 0.041343669250646, 'fraction_numerical': 0.028423772609819122, 'mean_word_length': 4.201342281879195, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 4, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Reduced growth of the adrenal zona glomerulosa after neonatal treatment of female rats with SRIH-14

array of biological actions, including the inhibition of hormone secretion, modulation of neural transmission and regulation of cell growth (F l o r i o et al., 1999). At the periphery, SRIH inhibits the secretion of several non-pituitary hormones such as insulin, glucagon, gastrin, secretin and aldosterone (R e i c h l i n , 1983; M i l o š e v i ć , 1999). Within the nervous system, SRIH acts as a neuromodulator, affecting neuroendocrine, motor, and cognitive functions (R e i c h l i n , 1983; E p e l b a u m et al., 1994). Because of its ability to inhibit secretory functions of various organs, its therapeutic value in clinical conditions is recognized and used.